Discontinued — last reported Q4 '23
A steady decline is expected due to amortization, while a sudden drop may signal an impairment charge, and an increase typically reflects additional capital investment or acquisitions.
This metric represents the carrying value of the Liletta product line's finite-lived intangible assets on the balance sh...
Comparable to net intangible asset balances for specific product lines or acquired portfolios reported by other life sciences companies.
abbv_segment_liletta_finite_lived_intangible_assets_net| Q4 '23 | |
|---|---|
| Value | $561.00M |